Adaptimmune Therapeutics Price to Free Cash Flow Ratio 2015-2021 | ADAP

Historical price to free cash flow ratio values for Adaptimmune Therapeutics (ADAP) since 2015. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Adaptimmune Therapeutics Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2021-10-15 5.33 0.00
2021-06-30 4.26 $-0.85 0.00
2021-03-31 5.31 $-0.84 0.00
2020-12-31 5.39 $-0.39 0.00
2020-09-30 7.98 $-0.29 0.00
2020-06-30 10.01 $-0.47 0.00
2020-03-31 2.72 $-0.60 0.00
2019-12-31 1.20 $-1.09 0.00
2019-09-30 1.51 $-1.34 0.00
2019-06-30 4.02 $-0.88 0.00
2019-03-31 4.30 $-0.94 0.00
2018-12-31 5.75 $-1.11 0.00
2018-09-30 13.56 $-1.04 0.00
2018-06-30 11.87 $-1.08 0.00
2018-03-31 11.23 $-0.85 0.00
2017-12-31 6.68 $-0.89 0.00
2017-09-30 8.19 $-0.65 0.00
2017-06-30 4.49 $-1.03 0.00
2017-03-31 5.51 $-1.12 0.00
2016-12-31 4.05 $-0.84 0.00
2016-09-30 7.05 $-0.80 0.00
2016-06-30 8.15 $-0.87 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.832B $0.004B
Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00